Psychopharmacology of Psilocybin in Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00465595

Recruitment Status : Active, not recruiting

First Posted : April 25, 2007

Last Update Posted : October 12, 2016

Sponsor:

Collaborator:

Heffter Research Institute

Information provided by (Responsible Party):

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Results Submitted - Not Posted on ClinicalTrials.gov

Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

Recruitment Status :	Active, not recruiting
Actual Primary Completion Date :	December 2014
Estimated Study Completion Date :	December 2016

Submission Cycle	Results Submitted to ClinicalTrials.gov	Results Returned after Quality Control Review
1	January 26, 2017	March 15, 2017
2	May 15, 2018

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016 Dec;30(12):1181-1197.

To Top